Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- forearm blood flow response
研究概览
简要总结
Various studies have reported cardioprotective effects of mineralocorticoid receptor (MR) antagonists in the setting of an acute myocardial infarction. In a recent animal study, the protective effect of MR antagonists on infarct size was completely abolished in CD73 knock-out and adenosine A2b receptor knock-out mice, and by co-administration of adenosine receptor antagonists in rats. These findings suggest that extracellular formation of adenosine is crucial for this protective effect and that MR antagonists stimulate extracellular adenosine formation by the enzyme CD73.
To investigate whether eplerenone promotes adenosine receptor stimulation by activating CD73, the investigators will measure forearm blood flow in response to various dosages of dipyridamole with the use of plethysmography. Dipyridamole increases the extracellular endogenous adenosine concentration by inhibition of the ENT transporter and induces local vasodilation. Therefore, the vasodilator effect of dipyridamole accurately reflects extracellular adenosine formation by the CD73 enzyme.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 40 Years(Adult)
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Age 18-40 years
- •Written informed consent
排除标准
- •Hypertension (Blood pressure >140 mmHg and/or >90 mmHg - SBP/DBP-)
- •Hypotension (Blood pressure <100 mmHg and/or <60 mmHg -SBP/DBP-)
- •Diabetes Mellitus (fasting glucose > 6.9 mmol/L or random > 11.0 mmol/L in venous plasma)
- •History of any cardiovascular disease
- •Angina pectoris
- •History of chronic obstructive pulmonary disease (COPD) or asthma
- •Alcohol and/or drug abuse
- •Concomitant use of medication
- •Renal dysfunction (MDRD < 60 ml/min/1.73 m2)
- •Liver enzyme abnormalities (ALAT > twice upper limit of normality)
- •Serum potassium ≥ 4.8 mmol/L
- •Fasting total cholesterol > 6.0 mmol/L
- •Second/third degree AV-block on electrocardiography
研究组 & 干预措施
Placebo
fully mimicking placebo 50 mg bid during 8 days
干预措施: Placebo (Drug)
eplerenone
eplerenone 50 mg bid during 8 days
干预措施: Eplerenone (Drug)
结局指标
主要结局
forearm blood flow response
时间窗: 8 days
Forearm blood flow response to the intrabrachial administration of incremental dosages of dipyridamole, after treatment with eplerenone, compared to placebo. The forearm blood flow will be measured by plethysmography.
次要结局
- forearm blood flow(8 days)
